|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, the MMP-9 gene might be involved in the development of asthma through functional genetic polymorphisms.
|
16631427 |
2006 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of ORMDL3, phosphorylated (p)‑ERK and MMP‑9 were significantly greater in the asthma‑model group; however, in the group pretreated with budesonide their expression was reduced.
|
28358425 |
2017 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting inos and MMP-9 activities in an ovalbumin-induced murine asthma model.
|
23244755 |
2012 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus MMP-9 might not be a major gene for asthma.
|
16026590 |
2005 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MMP-9 -1562C>T and 836G>A (Arg279Gln) were not associated with asthma (p> or =0.15) or asthma severity (p> or =0.13), and TIMP-1 434T>C (Phe124Phe) was not associated with asthma in women (p = 0.094) or men (p = 0.207).
|
16061701 |
2005 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results showed that the mean serum levels of MMP-9 in the children with asthma (136.53 ± 29.96 ng/ml) were significantly higher than that in the healthy controls (45.08 ± 12.53 ng/ml; P<0.05).
|
22052126 |
2012 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the role of the AP-1 sites within the MMP-9 promoter and the effect of commonly used asthma pharmacotherapies in modulating human rhinovirus (HRV)-induced MMP-9 production have not yet been elucidated.
|
22461694 |
2012 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase 9 (MMP9) gene has been shown to be involved in the pathogenesis of allergic rhinitis (AR) and asthma.
|
22237587 |
2012 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functionally, MMP-9-deficient mice had more acute allergic inflammation than wild-type mice, suggesting that MMP-9 was protective against experimentally induced asthma.
|
19667087 |
2009 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was no association between IL-6 and MMP-9 with asthma duration, total IgE, AEC, number of allergens sensitized and degree of sensitization.
|
27780376 |
2017 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Despite chronic treatment with inhaled steroids mean MMP-9/EBC activity in asthma group was significantly higher than in healthy controls.
|
25650123 |
2015 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, we hypothesized that Ets-1 expression is increased in asthma and that it contributed to enhanced MMP-9 and tenascin expression.
|
14734780 |
2004 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude that circulating granulocytes from COPD patients and asthmatics do not display an abnormal secretion of MMP-9, and that granulocytes from asthmatics have an impaired ability to release TIMP-1 upon stimulation.
|
11167375 |
2001 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of Matrix Metalloproteinase 9 (<i>MMP-9</i>) Polymorphisms with Asthma Risk: A Meta-Analysis.
|
30931075 |
2019 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review addresses the current understanding of MMP-9 in human asthma, IPF, and COPD, and in animal models of these conditions.
|
12495928 |
2003 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have found that MMP-9 concentration in breath condensates of children with stable asthma was slightly higher in ELISA, than in the activity assay.
|
27395373 |
2017 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Rutin also inhibited the expression of matrix metalloproteinase 9, thereby aiding in prevention of airway remodelling in asthma thereby revealing to be a potent candidate in asthma therapy.
|
30181695 |
2018 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotyping of four HapMap derived tagging SNPs in the MMP-9 gene was performed using MALDI-TOF MS in three cross sectional study populations of German children (age 9-11; N = 4,264) phenotyped for asthma and atopic diseases according to ISAAC standard procedures.
|
20181264 |
2010 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase-2 (MMP-2) and MMP-9 have been implicated in extracellular matrix degradation in animal models of fibrosis and asthma.
|
16275889 |
2006 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MMP-1 and MMP-9 expression was increased in the nasal tissues of smokers with asthma and CRS via real-time PCR and western blot.
|
31653934 |
2019 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MMP-9 (gelatinase B) is recognized in chronic obstructive pulmonary disease (COPD) and now asthma as playing a central role in matrix degradation in injury, as well as contributing to the remodeling process.
|
21644819 |
2012 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A disintegrin and metalloproteinase 33 (ADAM33) and matrix metalloproteinase-9 (MMP9) appear to have important roles in asthma and COPD pathogenesis.
|
17403951 |
2007 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The high molecular weight (HMW) form of MMP-9 was significantly increased in severe asthma (P =.02).
|
14657859 |
2003 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, the authors refer to the studies on MMP-9 inhibition as a new perspective for increasing the effectiveness of treatment in asthma and COPD.
|
26123447 |
2016 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
AMs of asthma with a fast FEV<sub>1</sub> decline released a higher level of MMP-9 (8.52 ± 3.53 pg/mL, <i>p</i> < 0.05) than those of a slow FEV<sub>1</sub> decline (0.99 ± 0.20 pg/mL).
|
31547356 |
2019 |